Please assess the completion status of the following clinical trial:

Trial Title: Intrathecal Morphine for Cesarean Delivery

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy women (ASA 2)~* Between 18 and 45 years old~* Singleton term pregnancies~* Planned neuraxial anesthesia~Exclusion Criteria:~* Refusal to participate~* Known allergy or contraindication to any medication used in the study~* Significant medical or obstetrical disease (ASA ≥ 3)~* Opioid use disorder~* Chronic pain syndrome~* Daily or near daily opioid use within last 3 weeks.~* Patient receiving a Monoamine oxidase inhibitors (MOAi)

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 45 Years
- Healthy Volunteers: f

Study Arms:
- 50 micrograms (Type: ACTIVE_COMPARATOR): Patients in this arm will receive 50 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
- 150 micrograms (Type: ACTIVE_COMPARATOR): Patients in this arm will receive 150 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery
- 250 micrograms (Type: ACTIVE_COMPARATOR): Patients in this arm will receive 250 micrograms of morphine administered in the spinal fluid as part of their anesthesia for cesarean delivery

Based on this trial design, predict the completion outcome and termination type (if applicable).